Stanislaw Skaluba, MD
Advanced Heart Failure and Transplant Cardiology · Naperville, ILNPI 1528011988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in IL, where the typical reported total is $11,038.
Across 115 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$893
- Cvrx, Inc.$547
- E.r. Squibb & Sons, L.L.C.$438
- Novartis$338
- Bard Peripheral Vascular, Inc.$267
- Pfizer$220
- plus $1K from 15 others
Across 12 payments — averaging $3081.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$36K
- Merck$500
What the payments were for
- Food & beverage$3,84597%
- Education$140%
- Entertainment$1183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $893 |
| Cvrx, Inc. | 5 | $547 |
| E.r. Squibb & Sons, L.L.C. | 31 | $438 |
| Novartis | 17 | $338 |
| Bard Peripheral Vascular, Inc. | 2 | $267 |
| Pfizer | 7 | $220 |
| Opsens Inc. | 9 | $208 |
| Impulse Dynamics (USA) Inc. | 2 | $155 |
| Edwards Lifesciences | 1 | $154 |
| Cardiac Dimensions, Inc. | 1 | $143 |
| Bridgebio Pharma, Inc. | 2 | $135 |
| Daxor Corporation | 1 | $110 |
| Amgen | 6 | $102 |
| Merck | 3 | $60 |
| Medtronic | 3 | $49 |
| AstraZeneca | 3 | $44 |
| Boston Scientific | 1 | $32 |
| United Therapeutics Corporation | 1 | $26 |
| Imperative Care, Inc | 1 | $21 |
| Surmodics, Inc. | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$441
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$427
- OPTIMIZER$284
- RotarexS 6 F x 135 cm$163
- EVOQUE$154
- Attruby$126
- BVA-100$110
- Rotarex$104
- CardioMEMS HF System$101
How this compares
$3,977 in reported general payments places this provider in the 15th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 28 | $238,201 |
| OpsumitMacitentan | 18 | $234,397 |
| EliquisApixaban | 126 | $145,095 |
| EntrestoSacubitril/Valsartan | 125 | $142,592 |
| XareltoRivaroxaban | 85 | $107,870 |
| JardianceEmpagliflozin | 27 | $34,673 |
| Sildenafil Citrate | 68 | $22,958 |
| FarxigaDapagliflozin Propanediol | 20 | $21,452 |
| Repatha SureclickEvolocumab | 17 | $17,249 |
| Metoprolol Succinate | 596 | $7,860 |
| Isosorbide Dinitrate | 33 | $6,406 |
| BrilintaTicagrelor | 12 | $5,255 |
| VascepaIcosapent Ethyl | 18 | $3,470 |
| Atorvastatin Calcium | 380 | $3,405 |
| Rosuvastatin Calcium | 219 | $2,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $438 | $238,20128 claims |
| PfizerEliquis | $220 | $145,095126 claims |
| NovartisEntresto | $338 | $142,592125 claims |
| AstraZenecaFarxiga, Brilinta | $44 | $26,70732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Naperville
- Maria Rosa CostanzoNaperville$716K
- Ron OrenNaperville$50K
- Deep ShahNaperville$8K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.